These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT). Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014 [TBL] [Abstract][Full Text] [Related]
3. [A placebo-controlled, double-blind, randomized trial of single daily dose of anti-muscarinic drug solifenacin succinate in patients with overactive bladder]. Cardozo L; Lisec M; Milard R; Van Vierssen Trip O; Kuzmin I; Drogendijk TE; Huang AM Akush Ginekol (Sofiia); 2007; 46(5):55-7. PubMed ID: 17974184 [No Abstract] [Full Text] [Related]
4. The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: ameliorative effect of solifenacin succinate (Vesicare), a bladder-selective antimuscarinic agent, on overactive bladder symptoms, especially urgency episodes. Ohtake A; Sato S; Sasamata M; Miyata K J Pharmacol Sci; 2010; 112(2):135-41. PubMed ID: 20134114 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: A pooled analysis. Drinka PJ Am J Geriatr Pharmacother; 2006 Sep; 4(3):292-3; author reply 293. PubMed ID: 17062331 [No Abstract] [Full Text] [Related]
6. [Pharmacological and clinical profile of solifenacin succinate (Vesicare) developed as a new therapeutic agent for overactive bladder]. Ohtake A; Sato S; Ikeda K; Sasamata M; Miyata K Nihon Yakurigaku Zasshi; 2006 Dec; 128(6):425-32. PubMed ID: 17167217 [No Abstract] [Full Text] [Related]
7. Tolerability of solifenacin and oxybutynin immediate release in older (> 65 years) and younger (≤ 65 years) patients with overactive bladder: sub-analysis from a Canadian, randomized, double-blind study. Herschorn S; Pommerville P; Stothers L; Egerdie B; Gajewski J; Carlson K; Radomski S; Drutz H; Schulz J; Barkin J; Hirshberg E; Corcos J Curr Med Res Opin; 2011 Feb; 27(2):375-82. PubMed ID: 21175373 [TBL] [Abstract][Full Text] [Related]
8. Photodistributed lichenoid drug eruption secondary to solifenacin. Shalders K; Gach JE Clin Exp Dermatol; 2008 May; 33(3):340-1. PubMed ID: 18076676 [No Abstract] [Full Text] [Related]
9. Canadian cost-effectiveness analysis of solifenacin compared to oxybutynin immediate-release in patients with overactive bladder. Herschorn S; Vicente C; Piwko C J Med Econ; 2010; 13(3):508-15. PubMed ID: 20690893 [TBL] [Abstract][Full Text] [Related]
10. Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT - a double-blind, placebo-controlled trial. Vardy MD; Mitcheson HD; Samuels TA; Wegenke JD; Forero-Schwanhaeuser S; Marshall TS; He W Int J Clin Pract; 2009 Dec; 63(12):1702-14. PubMed ID: 19930331 [TBL] [Abstract][Full Text] [Related]
11. Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes. Garely AD; Lucente V; Vapnek J; Smith N Ann Pharmacother; 2007 Mar; 41(3):391-8. PubMed ID: 17341526 [TBL] [Abstract][Full Text] [Related]
12. Solifenacin significantly improves all symptoms of overactive bladder syndrome. Chapple CR; Cardozo L; Steers WD; Govier FE Int J Clin Pract; 2006 Aug; 60(8):959-66. PubMed ID: 16893438 [TBL] [Abstract][Full Text] [Related]
13. QT prolongation and torsade de pointes associated with solifenacin in an 81-year-old woman. Asajima H; Sekiguchi Y; Matsushima S; Saito N; Saito T Br J Clin Pharmacol; 2008 Dec; 66(6):896-7. PubMed ID: 18823303 [No Abstract] [Full Text] [Related]
14. Solifenacin treatment for overactive bladder in Hispanic patients: patient-reported symptom bother and quality of life outcomes from the VESIcare Open-Label Trial. Capo' JP; Laramée C; Lucente V; Fakhoury A; Forero-Schwanhaeuser S Int J Clin Pract; 2008 Jan; 62(1):39-46. PubMed ID: 18036164 [TBL] [Abstract][Full Text] [Related]
16. Solifenacin succinate for the treatment of overactive bladder. Hoffstetter S; Leong FC Expert Opin Drug Metab Toxicol; 2009 Mar; 5(3):345-50. PubMed ID: 19331596 [TBL] [Abstract][Full Text] [Related]
17. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. Yamaguchi O; Marui E; Kakizaki H; Itoh N; Yokota T; Okada H; Ishizuka O; Ozono S; Gotoh M; Sugiyama T; Seki N; Yoshida M; BJU Int; 2007 Sep; 100(3):579-87. PubMed ID: 17669143 [TBL] [Abstract][Full Text] [Related]
18. Solifenacin: scientific evidence in the treatment of overactive bladder. Santos JC; Telo ER Arch Esp Urol; 2010 Apr; 63(3):197-213. PubMed ID: 20431184 [TBL] [Abstract][Full Text] [Related]
19. [Treatment with solifenacin reduces urinary urgency and improves quality of life. Results of the non-interventional CAP-study]. Kalchthaler M; Mühlich S; Rothe P MMW Fortschr Med; 2011 Jan; 152 Suppl 4():119-24. PubMed ID: 21598462 [No Abstract] [Full Text] [Related]